Tg Therapeutics (TGTX) Assets Average (2011 - 2026)
Tg Therapeutics (TGTX) posted quarterly Assets Average of $1.3 billion for Q1 2026, up 109.99% year-over-year from $617.2 million in Q1 2025, and up 24.13% quarter-over-quarter from $1.0 billion in Q4 2025.
Tg Therapeutics (TGTX) Assets Average (2011 - 2026) Analysis & Trends
Tg Therapeutics' Assets Average history runs 16 years deep, the most recent figure standing at $1.3 billion for Q1 2026.
- In Q1 2026, Assets Average rose 109.99% year-over-year to $1.3 billion; the TTM figure through Mar 2026 stood at $1.3 billion (up 109.99% YoY), while the FY2025 annual figure was $820.5 million, up 80.86% from the prior year.
- Assets Average for Q1 2026 stood at $1.3 billion, up from $1.0 billion in the prior quarter.
- The five-year high for Assets Average was $1.3 billion in Q1 2026, with the low at $195.5 million in Q1 2023.
- The 5-year median for Assets Average is $351.5 million (2024), against an average of $493.2 million.
- The sharpest annual moves came in 2022 and 2026: Assets Average slumped 47.87% in 2022, then jumped 109.99% in 2026.
- Tg Therapeutics' Assets Average stood at $205.7 million in 2022, then surged by 60.56% to $330.3 million in 2023, then surged by 76.14% to $581.9 million in 2024, then jumped by 79.45% to $1.0 billion in 2025, then increased by 24.13% to $1.3 billion in 2026.
- Business Quant data shows TGTX's Assets Average at $1.3 billion in Q1 2026, $1.0 billion in Q4 2025, and $863.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Tg Therapeutics | 7.46 Bn | 6.78 Bn | 199.14 Mn | 1.58 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.58 Bn |
| Mar 31, 2026 | 1.30 Bn |
| Dec 31, 2025 | 1.04 Bn |
| Sep 30, 2025 | 863.82 Mn |
| Jun 30, 2025 | 679.65 Mn |
| Mar 31, 2025 | 617.19 Mn |
| Dec 31, 2024 | 581.85 Mn |
| Sep 30, 2024 | 493.61 Mn |
| Jun 30, 2024 | 387.27 Mn |
| Mar 31, 2024 | 351.46 Mn |
| Dec 31, 2023 | 330.33 Mn |
| Sep 30, 2023 | 275.96 Mn |
| Jun 30, 2023 | 209.11 Mn |
| Mar 31, 2023 | 195.47 Mn |
| Dec 31, 2022 | 205.73 Mn |
| Sep 30, 2022 | 234.78 Mn |
| Jun 30, 2022 | 277.35 Mn |
| Mar 31, 2022 | 341.33 Mn |
| Dec 31, 2021 | 394.66 Mn |
| Sep 30, 2021 | 445.54 Mn |